Evidence map›Paper›PMID 42320483›Full record

Trial reportCell reports. Medicine2026

Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.

Ming Liu, Xuhong Wang, Meizi Li, Enyue Yang, Aige Yang, Mingxia Yuan, Ruihua Dong, Guijun Qin, Ping Liu, Chengqian Li and 4 more

Registry-linked trialAbstract readRandomized Controlled TrialClinical Trial, Phase IClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell reports. Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06256523 (A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06256523 phase1 / phase2completednot on this map

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GZR18 Injection in Chinese Adult Patients With Type 2 Diabetes Mellitus (T2DM)

TypeinterventionalSponsorGan and Lee Pharmaceuticals, USARan2022 to 2023Enrolled72ConditionsType 2 DiabetesArmsGZR18, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ming LiuDepartment of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China. Electronic address: mingliu@tmu.edu.cn.
Xuhong WangDepartment of Endocrinology, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Meizi LiDepartment of Endocrinology, The Affiliated Hospital of Yanbian University, Yanbian, China.
Enyue YangOffice of Clinical Trials, The Affiliated Hospital of Yanbian University, Yanbian, China.
Aige YangDepartment of Endocrinology, The First Hospital of Hebei Medical University, Shijiazhuang, China.
Mingxia YuanDepartment of Endocrinology, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Ruihua DongResearch Ward, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Guijun QinDepartment of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ping LiuDepartment of Endocrinology, General Hospital of Ningxia Medical University, Yinchuan, China.
Chengqian LiDepartment of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao, China.
Yu CaoClinical Research Center, The Affiliated Hospital of Qingdao University, Qingdao, China.
Jing ZhaoGan & Lee Pharmaceuticals, Beijing, China.
Liyuan ZhaoGan & Lee Pharmaceuticals, Beijing, China.
Wei ChenGan & Lee Pharmaceuticals, Beijing, China; Gan & Lee Pharmaceuticals Shandong Co., Ltd, Linyi, China. Electronic address: weichen45@126.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

GZR18 is a long-acting glucagon-like peptide-1 receptor agonist that is under development for the treatment of type 2 diabetes mellitus (T2DM). In this randomized, double-blind, placebo-controlled phase 1b/2a trial in Chinese adults with T2DM, the safety and efficacy of once-weekly GZR18 are evaluated using different dose-titration regimens in two separate parts: Part A (0.5-4 mg over 26 weeks) and Part B (1.5-13 mg over 23 weeks). Overall, 72 participants are enrolled, of whom 62 complete the trial. GZR18 significantly reduces glycated hemoglobin (HbA1c) in both parts (Part A: -1.32% for GZR18 versus 0.86% for placebo; Part B: -1.81% for GZR18 versus 0.12% for placebo). Improvements in body weight and other metabolic parameters are also observed. GZR18 is safe and well tolerated, with mostly mild-to-moderate gastrointestinal adverse events; no severe hypoglycemia or treatment-related serious adverse events occurred. These findings support further development of GZR18 in larger, longer-term trials. The trial is registered at ClinicalTrials.gov (NCT06256523).

Indexed as

Diabetes Mellitus, Type 2Glucagon-Like Peptide 1Hypoglycemic AgentsAdultAgedAsian PeopleChinaDouble-Blind MethodEast Asian PeopleFemaleGlucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHumansMaleMiddle AgedTreatment OutcomeGlucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsGlycated HemoglobinHypoglycemic AgentsbofanglutideGLP-1 receptor agonistGZR18HbA1ctype 2 diabetesweight control

Identifiers

PMID42320483
PMCPMC13400172

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.